Nonmyeloablative allogeneic stem cell transplant for the treatment of hematologic disorders

Trial Profile

Nonmyeloablative allogeneic stem cell transplant for the treatment of hematologic disorders

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Granulocyte colony-stimulating factors (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Methotrexate
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological disorders; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms MINI-HEME
  • Most Recent Events

    • 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top